LVAD DT denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for lvad dt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Your LVAD Destination Therapy as Not FDA-Approved — And Why You Can Appeal

Left ventricular assist device (LVAD) therapy used as destination therapy (DT) — meaning as a permanent, long-term support strategy rather than a bridge to transplant — has a defined regulatory history with the FDA. Aetna's "not FDA-approved" denial for this indication is one of the most commonly overturned denial types, because destination therapy has in fact received FDA approval for specific device models. The denial may stem from a documentation gap, a miscoding of the indication, or Aetna applying a policy to a device model that differs from the one actually implanted or proposed.

## Why This Denial Is Appealable

An insurer cannot legitimately deny coverage on a not-FDA-approved basis if the device in question carries FDA approval for the destination therapy indication. The first step in your appeal is establishing the exact regulatory status of the specific LVAD model at issue by consulting the FDA's 510(k) or PMA database and including that documentation in your appeal. Your prescribing cardiologist or heart failure specialist should provide a letter confirming the device's approved indication and explaining how it applies to your clinical situation.

## Federal Appeal Framework

You have layered rights under federal law:

• Internal appeal: Submit a written appeal within the timeframe stated in your denial letter (typically 180 days for ERISA plans). Aetna must respond within 60 days for standard appeals or 72 hours for urgent/expedited requests.
• External review (ACA §2719): After exhausting internal appeals, or if Aetna upholds the denial, you may request an independent external review. An accredited Independent Review Organization (IRO) evaluates whether the denial meets clinical and regulatory standards. The external review window is generally available within four months of receiving the final internal denial.
• Expedited review: If your condition is urgent or life-threatening, you may simultaneously request an expedited internal and external review — decisions are typically required within 72 hours.
• ERISA §503: If your coverage is employer-sponsored, ERISA requires a full-and-fair review of all evidence you submit.

## Documentation to Gather

• FDA approval documentation for the specific LVAD device model (PMA or 510(k) clearance letter)
• Diagnosis confirmation: cardiology records establishing advanced heart failure and the clinical basis for destination therapy
• Prior treatment history: documented courses of guideline-directed medical therapy with dates and outcomes showing inadequate response
• Clinical severity documentation: most recent echocardiogram, functional status assessments, and hemodynamic data from the chart
• Prescriber medical-necessity letter: a detailed letter from your heart failure specialist or cardiac surgeon explaining why destination therapy is medically necessary for your specific case
• Aetna's coverage policy: download Aetna's published clinical policy bulletin for LVAD/destination therapy so you can address each criterion directly

## Criteria-Mapping Structure

Organize your appeal as a point-by-point response. For each requirement in Aetna's coverage policy, write a one- or two-sentence answer citing the specific chart document and date that satisfies it. Confirm the device's FDA-approved indication and demonstrate that your clinical presentation meets the criteria stated in both the FDA-approved labeling and Aetna's own published policy. This structured format forces the reviewer to address each point individually rather than issuing a blanket denial.